Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction

scientific article published on 04 October 2013

Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.AMJCARD.2013.09.028
P932PMC publication ID3881171
P698PubMed publication ID24210333

P50authorWilliam B. KannelQ15439387
Emelia J. BenjaminQ28754501
Ramachandran S. VasanQ30348351
Michael J PencinaQ37382178
Philimon GonaQ38625598
Ralph B. D'Agostino Sr.Q59209521
Thomas J. WangQ80460150
Daniel LevyQ88264418
Raghava S VelagaletiQ114308524
Jayashri R AragamQ114427805
P2093author name stringDouglas S Lee
P2860cites workLongitudinal tracking of left atrial diameter over the adult life course: Clinical correlates in the communityQ33659377
Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart StudyQ34140511
The Natural History of Congestive Heart Failure: The Framingham StudyQ34701680
Wall stress and patterns of hypertrophy in the human left ventricleQ35194096
The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) studyQ37252005
Left ventricular architecture and survival in African-Americans free of coronary heart disease (from the Atherosclerosis Risk in Communities [ARIC] study)Q37269763
Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the framingham offspring studyQ37385696
Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood instituteQ37417065
Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurementsQ39605651
A comparative serial echocardiographic analysis of cardiac structure and function in rats subjected to pressure or volume overloadQ43519443
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic StudyQ46056330
Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).Q46587540
Left ventricular geometric patterns in the Jackson cohort of the Atherosclerotic Risk in Communities (ARIC) Study: clinical correlates and influences on systolic and diastolic dysfunctionQ46606495
Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart studyQ48491751
Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction.Q50957875
Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study.Q51896569
Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.Q52429603
Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential HypertensionQ52455174
Surgical ventricular restoration in patients with ischemic dilated cardiomyopathy: Evaluation of systolic and diastolic ventricular function, wall stress, dyssynchrony, and mechanical efficiency by pressure-volume loopsQ57298877
Prognosis of left ventricular geometric patterns in the Framingham heart studyQ57740676
An investigation of coronary heart disease in families. The Framingham offspring studyQ59461737
Prognostic value of left ventricular hypertrophy and geometry in patients with a first, uncomplicated myocardial infarctionQ62818473
M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study)Q73870544
Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure?Q74364485
Device-based change in left ventricular shape: a new concept for the treatment of dilated cardiomyopathyQ74486719
Epidemiological approaches to heart disease: the Framingham StudyQ75689289
Left ventricular geometry and mortality in patients >70 years of age with normal ejection fractionQ79393159
Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patientsQ79749033
Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricleQ80055213
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectheart failureQ181754
ejection fractionQ641303
left ventricular hypertrophyQ1628627
P304page(s)117-122
P577publication date2013-10-04
P1433published inAmerican Journal of CardiologyQ2208417
P1476titleLeft ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction
P478volume113

Reverse relations

cites work (P2860)
Q55279096"Frailty, thy name is woman": syndrome of women with heart failure with preserved ejection fraction.
Q38764956Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine
Q36046811Age, Gender and Load-Related Influences on Left Ventricular Geometric Remodeling, Systolic Mid-Wall Function, and NT-ProBNP in Asymptomatic Asian Population
Q33732380Alterations in cardiac structure and function in hypertension
Q38893111Ambulatory Blood Pressure Parameters and Heart Failure With Reduced or Preserved Ejection Fraction in Elderly Treated Hypertensive Patients
Q46310992An exploratory investigation of echocardiographic parameters and the effects of posture on cardiac structure and function in the Livingstone's fruit bat (Pteropus livingstonii).
Q36074394Association of a 4-Tiered Classification of LV Hypertrophy With Adverse CV Outcomes in the General Population.
Q30692600Cardiovascular Health Status and Incidence of Heart Failure in the Framingham Offspring Study
Q38726519Dietary management of heart failure: room for improvement?
Q89674863Do We Need to Know the Left Ventricular Geometry Patterns of the Brazilian Population?
Q37219607ECG low QRS voltage and wide QRS complex predictive of centenarian 360-day mortality
Q53590491Electrocardiographic Left Ventricular Hypertrophy as a Predictor for Nonsignificant Coronary Artery Disease in Patients With Non-ST-Segment Elevation Myocardial Infarction.
Q57308303Epidemiology of heart failure with preserved ejection fraction
Q58127115Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA
Q40296294Fitness in Young Adulthood and Long-Term Cardiac Structure and Function: The CARDIA Study
Q64100032Galectin-3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients
Q37637447Heart Failure in Women--Insights from the Framingham Heart Study
Q26747554Heart Failure with Preserved Ejection Fraction - Concept, Pathophysiology, Diagnosis and Challenges for Treatment
Q28066310Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus
Q47179239Impact of echocardiography on one-month and one-year mortality of intertrochanteric fracture patients
Q38209968Myocardial remodeling in hypertension
Q89523491Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy
Q30384457Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation.
Q88747990Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF
Q91037375Recent advances in understanding the roles of T cells in pressure overload-induced cardiac hypertrophy and remodeling
Q60922030Role of spironolactone in the treatment of heart failure with preserved ejection fraction
Q35548448The lipid peroxidation product 4-hydroxy-trans-2-nonenal causes protein synthesis in cardiac myocytes via activated mTORC1-p70S6K-RPS6 signaling

Search more.